1428183-79-2

Basic information

• Product Name: 3,5-dimethyl-1-[2-(trifluoromethyl)phenyl]-1H-pyrazole
• Synonyms: 3,5-dimethyl-1-[2-(trifluoromethyl)phenyl]-1H-pyrazole
• CAS NO: 1428183-79-2
• Molecular Weight: 240.228
• Mol File: 1428183-79-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3,5-dimethyl-1-[2-(trifluoromethyl)phenyl]-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-dimethyl-1-[2-(trifluoromethyl)phenyl]-1H-pyrazole(1428183-79-2)
• EPA Substance Registry System: 3,5-dimethyl-1-[2-(trifluoromethyl)phenyl]-1H-pyrazole(1428183-79-2)

Safety Data

• Hazardous Substances Data: 1428183-79-2(Hazardous Substances Data)

Upstream product

• 365-34-4 2-(trifluoromethyl)phenylhydrazine 
• 123-54-6 acetylacetone 

Downstream Products

• 1428183-80-5 3,5-dimethyl-1-[2-(trifluoromethyl)phenyl]pyrazole-4-carbaldehyde 
• 1428183-84-9 C₂₁H₂₀F₃N₃O₃ 
• 95430-69-6 1,1-bis(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)methane 

Relevant articles and documents

Oxone-DMSO Triggered Methylene Insertion and C(sp2)-C(sp3)-H-C(sp2) Bond Formation to Access Functional Bis-Heterocycles

Metal-free insertion of a methylene group was achieved for the construction of a new C(sp2)-C(sp3)-H-C(sp2) bond in order to prepare novel bis-heterocyclic scaffolds. The complete mechanistic investigations included experimental study and DFT calculations, and various symmetric and unsymmetric bis-pyrazoles as well as other pyrazole-based bis-heterocyclic molecules were prepared in moderate to high yields. Further modification of the bridged methylene group in the unsymmetric pyrazoles generated a chiral center to extend the scope of this method.

Discovery and structure-activity relationships of pyrrolone antimalarials

In the pursuit of new antimalarial leads, a phenotypic screening of various commercially sourced compound libraries was undertaken by the World Health Organisation Programme for Research and Training in Tropical Diseases (WHO-TDR). We report here the detailed characterization of one of the hits from this process, TDR32750 (8a), which showed potent activity against Plasmodium falciparum K1 (EC50 ～ 9 nM), good selectivity (>2000-fold) compared to a mammalian cell line (L6), and significant activity against a rodent model of malaria when administered intraperitoneally. Structure-activity relationship studies have indicated ways in which the molecule could be optimized. This compound represents an exciting start point for a drug discovery program for the development of a novel antimalarial.